"We are very pleased to report record revenue during the third quarter of 2005, which was driven by a substantial increase in activity at our core sites," commented Judi Irving, President and Chief Executive Officer. "Our blood product operations in California and on the East Coast have grown steadily and the gross profits from these centers continue to improve." Ms. Irving further commented, "We are also pleased with the progress we have made in our blood services business segment. Although revenue and gross profit for this segment are down from the levels reported during the third quarter of 2004, revenue and gross profit are improving from levels reported earlier in 2005. We are experiencing steadily increasing procedure volumes compared to early in 2005 as the result of our marketing programs highlighting HemaCare's proven capability and expertise." Ms. Irving concluded, "The Company continues to move in a positive direction. After eight consecutive profitable quarters since the restructuring in late 2003, the Company's financial position is strong and continues to improve. With the resources generated by our ongoing profitable operations we are reducing our outstanding debt, and investing in our infrastructure to enhance our capability to provide products and services to our customers."

HemaCare will be holding an interactive investor conference call on Thursday, November 10, 2005 at 1:00 PM (Eastern Standard Time). Judi Irving, President and CEO, and Robert Chilton, Executive Vice President and CFO, will review the third quarter 2005 financial results. To participate in the call, please call 800-309-8563 and ask to join HemaCare's third quarter earnings conference call. A recording will be available two hours following the call through midnight, November 18, 2005 that can be replayed by calling 800-642-1687, ID number 1860706. A webcast of the conference call will also be available via the Company's website (www.hemacare.com ) after November 18, 2005.

Founded in 1978, HemaCare is a provider of blood products and services to the healthcare industry in the U. S. HemaCare is licensed by the Food and Drug Administration and accredited by the American Association of Blood Banks. The Company focuses on providing cost-effective, high-quality solutions to organizations with a need for blood-related products and services.

This press release contains "forward-looking statements" under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements herein that are not historical facts are forward-looking statements pursuant to the safe harbor provisions referenced above. You may also identify forward-looking statements by use of the words "anticipates," "expects," "intends," "plans" and variations and similar expressions. Forward-looking statements are inherently subject to risks and uncertainties some of which cannot be predicted or quantified. Such risks and uncertainties include, without limitation the Company's need to successfully complete its operating plan to improve profit; the potential loss of the Company's lines of credit; the potential inability of the Company to meet future capital needs; increasing costs that the Company may not be able to pass on to customers because the market price for blood does not necessarily reflect the costs of collecting and processing it; declining blood donations; the Company's dependence on reimbursement rates of third party providers; its increasing reliance on outside laboratories; limited access to insurance; the competitive advantage enjoyed by not-for-profit companies in the Company's industry; potential changes in the healthcare industry; future technology for blood collection and blood replacement; the need to obtain services of qualified medical professionals; the impact of heavy regulation in the Company's industry; potential liability for undetected blood pathogens and other product safety and liability concerns; environmental risks associated with biohazardous substances; the threat of business interruption due to terrorism and the security measures taken in response to terrorism; the provisions of the Company's charter documents that might delay or prevent an acquisition or sale of the Company; lack of liquidity and market risk associated with OTC Bulletin Board stocks; volatility in our stock price; potential dilution that could result from future sales of the Company's common stock; and the other risks and uncertainties discussed from time to time in the documents HemaCare files with the Securities and Exchange Commission. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct. Consequently, future events and actual results could differ materially from those set forth in, contemplated by, or underlined in the forward-looking statements contained herein. The Company undertakes no obligation to update any of these forward-looking statements to reflect actual results or events or circumstances after the date hereof.

This is cache, read story here